-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Biogen, Lowers Price Target to $199

Benzinga·04/29/2025 16:26:49
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $210 to $199.